The Law Offices of Howard G. Smith launched the action following claims that Capricor executives issued false statements between December 17, 2025, and July 26, 2026. The complaint alleges the company modified its statistical analysis plan for the drug Deramiocel without prior FDA consent, creating a hidden risk that the agency would reject the treatment for Duchenne muscular dystrophy.
Plaintiffs argue that by failing to disclose these internal changes and the subsequent uncertainty regarding regulatory approval, the company misled shareholders about its operational viability. Those who suffered losses are not required to take immediate action to remain part of the class, though they may consult with counsel to explore their rights before the court-mandated deadline.
Comments (0)
No comments yet. Be the first!